Pediatric Dermatology

The study stated early recognition and aggressive treatment of childhood-onset MMP are essential to prevent permanent scarring.

Mercedes E. Gonzalez, MD, reflects on the SPD meeting as well as challenges and advances in pediatric dermatology.

Compared to placebo, there was a 70% reduction in IgE levels in children ages 0.5 to 6 after 16 weeks of therapy.

Experts discussed pediatric atopic dermatitis, treatment innovations, disease burden, and the latest topical and systemic therapies in a DermView video series.

A PDUFA target action date has been set for October 13, 2025.

At the Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, presented a case of a female patient aged 12 years with moderate AD that had been worsening over the past several months.

Researchers reported that propranolol initiation for infantile hemangiomas in pediatric patients is safe, with no significant complications, suggesting reduced need for intensive monitoring.

Lead author on recent research, Lawrence Eichenfield, MD, said if approved, this treatment could fill a “significant gap.”

The promotion of anti-aging products to children, who don't yet experience age-related skin changes, is both ethically questionable and potentially harmful.

Patients aged 6 to 12 had little to no adverse events and no pharmacokinetic abnormalities were noted.

A new review highlights overall allergen rates among children in the United States between 2010 and 2024.

Researchers analyzed stratum corneum hydration and transepidermal water loss across 15 regions of the skin.

If granted, guselkumab will be approved to treat children ages 6 and younger with severe plaque psoriasis and children ages 5 and younger with juvenile psoriatic arthritis.

Pediatric melanoma, though rare, is the deadliest skin cancer in children, with 300-500 US cases annually.

At the SDPA Fall Conference, Miranti emphasized the importance of targeted, comprehensive acne therapies and inspired attendees to embrace pediatric dermatology as a rewarding subspecialty.

The LIBERTY-AD PED-OLE study showed clinical remission for moderate to severe atopic dermatitis.

Survey results presented at ACAAI’s annual Scientific Meeting demonstrate the limited influence of elimination diets for reducing symptoms of AD.

With this combined administration, patients saw noticeable and lasting improvements in severe cases of AD.

A recent review found hair loss can severely impact self-esteem and body image, leading to social anxiety and emotional distress among affected youth.

The trial showcased the continued efficacy of apremilast, with 2-year data on the forefront.

The review assessed infections, gastrointestinal AEs, blood and lymphatic disorders, and nervous system and musculoskeletal/connective tissue disorders.

Dermatology Times spoke with Leah Howard, JD, of the NPF, and Trisha, the mother of a young girl with psoriasis, to discuss Otezla's implications in the therapeutic landscape.

Bullous pemphigoid in youth is rare and can be missed due to negative BP180 ELISA results, complicating timely diagnosis in children.

Approximately 8.8% of patients achieved complete response a year after onset of diphenylcyclopropenone therapy.

John Browning, MD, FAAD, FAAP, MBA, discusses the new online platform that allows young patients to share their skin journey with others.

Michele Ramien, MD, discusses biologic therapies for pediatric dermatology, focusing on their impact on vaccines, managing side effects, and tailoring treatment.

From ER visits for dystrophic epidermolysis bullosa to rates of axillary hyperhidrosis, catch up on top pediatric insights from July.

Researchers conducted an assessment of the Nationwide Emergency Department Sample to analyze frequency of visits attributed to young patients with DEB.

A recent case series reviewed the treatment patterns and effects of therapies on 89 pediatric patients with CCD.

Four APPs emphasized the vital role of advanced practice providers in improving patient care and expanding service access.